November 20, 2017

CMS Releases 2018 Clinical Laboratory Fee Schedule

AlloMap 2018 Rate Increase Confirmed

BRISBANE, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announces that CMS released the 2018 Clinical Laboratory Fee Schedule confirming that the AlloMap reimbursement rate will be increased to $3,240.

The Center for Medicare and Medicaid Services (CMS) released the final 2018 Clinical Laboratory Fee Schedule (CLFS) today, re-affirming the preliminary rate for AlloMap of $3,240, an increase of 14% compared with the 2017 CMS CLFS rate of $2,840.75. The higher 2018 reimbursement rate for AlloMap was due in part to effective claims management, which increased the weighted median of commercial reimbursement. This data was shared with CMS as required by regulations associated with the Protecting Access to Medicare Act of 2014 (PAMA). The effective date of the increase is January 1, 2018.

"The implementation of PAMA by CMS provides a refreshing predictability to the reimbursement of diagnostic tests," said Sasha King, Chief Commercial Officer at CareDx . "The updated rate highlights the value AlloMap brings to heart transplant patients."

About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.

For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release contains forward-looking statements about our business, research, development and commercialization efforts. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed by us with the SEC on April 21, 2017 and the periodic reports that we have subsequently filed with the SEC. Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Commercial Officer
415-287-2393
sking@caredx.com

Investor Relations
David Clair
Integrated Corporate Relations, Inc.
646-277-1266
david.clair@icrinc.com

Source: CareDx, Inc.